Advanced Biological Laboratories (ABL) Offers Early Access to its Innovative HCV NS5B Kit for Streamlined Characterization of HCV-Infected Patients' Genotypes and Subtypes

The first HCV genotyping assay combined with software to deliver a fast and high confidence interpretation and reporting on genotype and subtyping from Sanger and next generation sequencing data, for molecular pathologists and hepatologists.

LUXEMBOURG VILLE, Luxembourg, July 13, 2015 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A. today announces that it is enrolling molecular diagnostic laboratories in an Early Access Program (EAP) to facilitate the access of its innovative test branded "DeepChek® HCV NS5B Assay". The DeepChek® end-to-end solution identifies viral hepatitis C (HCV) genotypes and subtypes – key elements for justifying and determining personalized anti-HCV treatment - from HCV RNA NS5B gene amplification, ready for sequencing, and sequence data analysis with DeepChek® HCV analysis software.

In the current market the DeepChek® HCV NS5B is a highly affordable HCV genotyping test and easy-to-perform assay. It generates a very reliable amplicon, ready for Sanger or next generation sequencing (NGS) with clinical reporting included, to potentially determine with high resolution and more accurately than current existing commercial tests, any HCV genotype and subtype.

Any laboratory performing standard HCV genotyping and subtyping tests and using routine sequencing and NGS, will be eligible to join the EAP. ABL and the EAP-participants will closely work together to assure optimal results.

"The DeepChek® HCV NS5B test and software are an innovative end-to-end solution offering molecular laboratories the opportunity to have a more accurate test, using sequencing. This will simplify and streamline the interpretation and reporting process and provide consistent, high-quality and actionable results for use in clinical research and decision making as an integral part of treatment care" says Dr Chalom B. Sayada, CEO of ABL Group.

The launch of the Early Access Program for HCV NS5B is paving the way for other tests to be offered by the ABL Group with HCV drug resistance genotyping assays.

The ABL Group is also commercialising, for research use only (RUO), HIV reagents for reverse transcriptase, protease and integrase, also available for Sanger and NGS, combined with DeepChek® HIV software, CE-marked for IVD use.

About ABL: Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC® and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL France is developing reagents for infectious diseases which are bundled with ABL's softwares as an end-to-end solution.

Media Contact: Chalom SAYADA, Advanced Biological Laboratories, +35226388921, early-access@ablsa.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Advanced Biological Laboratories



2017

Tags

Biotechnology, Health Care & Hospitals, Infection Control, Medical Equipment, New Products & Services


More by this company


Need Help